Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 527

Sort by

Sort Order Select

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Marco Basset, Irene Defrancesco, Paolo Milani, Mario Nuvolone, Sara Rattotti, Andrea Foli, Silvia Mangiacavalli, Marzia Varettoni, Pietro Benvenuti, Claudio Salvatore Cartia, Marco Paulli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini

Blood (2020) 135 (4): 293–296.

https://doi.org/10.1182/blood.2019002762

Published: 2020

Journal Articles

Constipated plasma cells in extranodal marginal zone lymphoma of the lung

Jinjun Cheng, Elaine S. Jaffe

Blood (2019) 134 (24): 2226.

https://doi.org/10.1182/blood.2019003455

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2019) 134 (Supplement_1): 762.

https://doi.org/10.1182/blood-2019-122451

Published: 2019

Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Blood (2019) 134 (Supplement_1): 767.

https://doi.org/10.1182/blood-2019-124177

Published: 2019

Journal Articles

An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data

Wolfgang Kern, MD, Franz Elsner, PhD, Max Zhao, Nanditha Mallesh, Richard Schabath, PhD, Claudia Haferlach, MD, Peter Krawitz, MD, Hannes Lueling, PhD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 886.

https://doi.org/10.1182/blood-2019-130374

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, MD, Panayiotis Panayiotidis, MD, George A Follows, MD PhD, Luigina Mollica, MD FRCPC, PhD, Arnon Nagler, MD MSc, Muhit Özcan, MD, Armando Santoro, Don Stevens, MD, David Trevarthen, MD, Florian Hiemeyer, MSc, Li Liu, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 1531.

https://doi.org/10.1182/blood-2019-121932

Published: 2019

Journal Articles

High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries

Edward Briercheck, MD, Fabiola Valvert, MD, Elizabeth Solorzano, MSc, Oscar Silva, MD PhD, Maneka Puligandla, MS, Marcos Mauricio Siliézar Tala, MD, Timothy Guyon, MSc, Samuel L. Dixon, BS, Robert Terbrueggen, PhD, Yasodha Natkunam, MD PhD, Kristen E. Stevenson, MS, David M Weinstock

Blood (2019) 134 (Supplement_1): 409.

https://doi.org/10.1182/blood-2019-121397

Published: 2019

Journal Articles

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

Theodora Anagnostou, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Shahrzad Jalali, PhD, Jose C Villasboas, Hongyan Wu, PhD, Tammy Price-Troska, BS, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2790.

https://doi.org/10.1182/blood-2019-127757

Published: 2019

Journal Articles

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Alberto J Arribas, Sara Napoli, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Alessandra Di Veroli, Chiara Tarantelli, PhD, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, PhD, Andrea Rinaldi, Anastasios Stathis, MD, Georg Stuessi, MD, Valter Gattei, MD, Gabriele Cruciani, Emanuele Zucca, MD, Davide Rossi, MD PhD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2569.

https://doi.org/10.1182/blood-2019-124299

Published: 2019

Journal Articles

Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas

Luis Colomo, Ivonne Vazquez, Natalia Papaleo, Marta Salido, Anna Puiggros, Blanca Espinet, Maria Rodriguez-Rivera, Ramon Diez-Feijoo, Blanca Sanchez-Gonzalez, Antonio Salar, Ana Ferrer, Leonor Arenillas, Marcio Andrade Campos, MD PhD, Xavier Calvo

Blood (2019) 134 (Supplement_1): 2899.

https://doi.org/10.1182/blood-2019-125717

Published: 2019

Journal Articles

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Ming Hao, PhD, Su Yang, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 2876.

https://doi.org/10.1182/blood-2019-127751

Published: 2019

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

Shi Hui Clarice Choong, MBBS, MRCP, Wee-Joo Chng, MBBS, PhD, Sanjay De Mel, BSc, BM, Te-Chih Liu, FRCPath, MBBS, MRCP, Bei Jenny Li, Li Mei Michelle Poon, Shir Ying Lee, FRCPath,MBBS,MRCP,, Hoon Chung Tae, Rebecca Teng, Seok Wei Stephrene Chan

Blood (2019) 134 (Supplement_1): 5253.

https://doi.org/10.1182/blood-2019-125241

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Clare Gould, MBBS, Jennifer Lickiss, MSc, BSc, Yamuna Kankanige, Satwica Yerneni, MS, John Markham, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Diego Villa, MD MPH, Graham W Slack, MD, Collin Chin, MBBS, Constantine S. Tam, MBBS (Hons), MD, Stephen Lade, MBBS, FRCPA, Niles Elizabeth Nelson, BSc, MBBS, Paul J Neeson, BSc, PhD, John F. Seymour, MBBS, PhD FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 4290.

https://doi.org/10.1182/blood-2019-127800

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Constipated plasma cells in extranodal marginal zone lymphoma of the lung

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

High Accuracy, Low-Cost Transcriptional Diagnostic to Transform Lymphoma Care in Low- and Middle-Income Countries

Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas

Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only